Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna—A Randomized,Cross-Over Clinical Study

Purpose

Chemotherapy-induced cognitive impairment (CICI) is a common sequelae of cancer therapy. Recent preclinical observations have suggested that CICI can be mediated by chemotherapy-induced plasma protein oxidation, which triggers TNF-α mediated CNS damage. This study evaluated sodium-2-mercaptoethane sulfonate (Mesna) co-administration with doxorubicin to reduce doxorubicin-induced plasma protein oxidation and resultant cascade of TNF-α, soluble TNF receptor levels and related cytokines.

Methods

Thirty-two evaluable patients were randomized using a crossover design to receive mesna or saline in either the first or second cycle of doxorubicin in the context of a standard chemotherapy regimen for either non-Hodgkin lymphoma or breast cancer. Mesna (360 mg/m²) or saline administration occurred 15 minutes prior and three hours post doxorubicin. Pre-treatment and post-treatment measurements of oxidative stress, TNF-α and related cytokines were evaluated during the two experimental cycles of chemotherapy.

Results

Co-administration of mesna with chemotherapy reduced post-treatment levels of TNF-related cytokines and TNF-receptor 1 (TNFR1) and TNF-receptor 2 (TNFR2) (p = 0.05 and p = 0.002, respectively). Patients with the highest pre-treatment levels of each cytokine and its receptors were the most likely to benefit from mesna co-administration.

Conclusions

The extracellular anti-oxidant mesna, when co-administered during a single cycle of doxorubicin, reduced levels of TNF-α and its receptors after that cycle of therapy, demonstrating for the first time a clinical interaction between mesna and doxorubicin, drugs often coincidentally co-administered in multi-agent regimens. These findings support further investigation to determine whether rationally-timed mesna co-administration with redox active chemotherapy may prevent or reduce the cascade of events that lead to CICI.

Trial Registration

clinicaltrials.gov NCT01205503.     

Anticancer Activities of 7-, and 9-Substituted 3-Deazaguanine Derivatives

Abstract

Interesting differences in anticancer activities of 7- and 9-substituted derivatives of 3-deazaguanine are described.     

Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by β3 integrin signaling

Atheroma formation and restenosis following percutaneous vascular intervention involve the growth and migration of vascular smooth muscle cells (SMCs) into neointimal lesions, in part due to changes in the extracellular matrix. While some clinical studies have suggested that, in comparison to non-diabetics, β3 integrin inhibition in diabetic patients confers protection from restenosis, little is known regarding the role of β3 integrin inhibition on SMC responses in this context. To understand the molecular mechanisms underlying integrin-mediated regulation of SMC function in diabetes, we examined SMC responses in diabetic mice deficient in integrin β3 and observed that the integrin was required for enhanced proliferation, migration and extracellular regulated kinase (ERK) activation. Hyperglycemia-enhanced membrane recruitment and catalytic activity of PKCβ in an integrin β3-dependent manner. Hyperglycemia also promoted SMC filopodia formation and cell migration, both of which required αVβ3, PKCβ, and ERK activity. Furthermore, the integrin–kinase association was regulated by the αVβ3 integrin ligand thrombospondin and the integrin modulator Rap1 under conditions of hyperglycemia. These results suggest that there are differences in SMC responses to vascular injury depending on the presence or absence of hyperglycemia and that SMC response under hyperglycemic conditions is largely mediated through β3 integrin signaling.     

Neural stem cell properties of Müller glia in the mammalian retina: regulation by Notch and Wnt signaling

The retina in adult mammals, unlike those in lower vertebrates such as fish and amphibians, is not known to support neurogenesis. However, when injured, the adult mammalian retina displays neurogenic changes, raising the possibility that neurogenic potential may be evolutionarily conserved and could be exploited for regenerative therapy. Here, we show that Müller cells, when retrospectively enriched from the normal retina, like their radial glial counterparts in the central nervous system (CNS), display cardinal features of neural stem cells (NSCs), i.e., they self-renew and generate all three basic cell types of the CNS. In addition, they possess the potential to generate retinal neurons, both in vitro and in vivo. We also provide direct evidence, by transplanting prospectively enriched injury-activated Müller cells into normal eye, that Müller cells have neurogenic potential and can generate retinal neurons, confirming a hypothesis, first proposed in lower vertebrates. This potential is likely due to the NSC nature of Müller cells that remains dormant under the constraint of non-neurogenic environment of the adult normal retina. Additionally, we demonstrate that the mechanism of activating the dormant stem cell properties in Müller cells involves Wnt and Notch pathways. Together, these results identify Müller cells as latent NSCs in the mammalian retina and hence, may serve as a potential target for cellular manipulation for treating retinal degeneration.     

Influence on chromosome behaviour,nucleic acid content and ultra-structural analysis of accessories inUrginea indica KUNTH.

The occurrence of polysomaty was noted in a diploid cytotype ofUrginea indica with B chromosomes. These accessories could be clearly distinguished from the other chromosomes in their stainability, very small size, morphology, variability and irregular behaviour. The variant nuclei were hyperdiploid, hypertriploid and hypertetraploid. B chromosomes were noted only in diploid cells and no accessories could be recorded in cells showing higher chromosome number. The amount of DNA content as indicated by the absorbance is rather low as compared to the diploid without accessories which may be due to the shorter size of the chromosomes. Under ultrastructural study subterminal centromeric region of B chromosome show low electron dense appearance.     

Synthesis, structure and luminescence behaviour of a mononuclear cadmium(II) dicyanamide and a coordination polymer of mercury(II) dicyanamide containing 2,2′-dipyridylamine (dpaH) as end-capping ligand/anion of dpaH as binucleating bridge. Variance in coordination numbers, nuclearities and architectures with metal ion templates

A mononuclear compound [Cd(dpaH)₂(dca)₂] (1) and a tetranuclear based 2D coordination polymer [Hg₄(dpa)₄(dca)₄]_n (2) [dpaH = 2,2′-dipyridylamine, dpa = anion of dpaH, dca = dicyanamide] have been synthesized and characterized. X-ray structural analyses reveal that cadmium(II) center in 1 has a distorted octahedral geometry with a CdN₆ chromophore ligated through two bidentate neutral dpaH units along with two nitrile N atoms of two terminally bound dca units in mutual cis orientation. Each of the four independent mercury(II) centers in 2 adopts a distorted trigonal bipyramidal environment coordinated by two pyridine N atoms of two different anionic dpa ligands, two nitrile N atoms of two μ_1,5 bridged dca units and the fifth position is occupied by the amide N of one dpa. Cooperative intermolecular N-H···N and C-H···N hydrogen bondings promote dimensionality in 1. The compounds display intraligand ¹(π-π^∗) fluorescence in DMF solutions at room temperature.     

Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing

Monoclonal antibodies targeting the Epidermal Growth Factor Receptor (EGFR), such as cetuximab and panitumumab, have evolved to important therapeutic options in metastatic colorectal cancer (CRC). However, almost all patients with clinical response to anti-EGFR therapies show disease progression within a few months and little is known about mechanism and timing of resistance evolution. Here we analyzed plasma DNA from ten patients treated with anti-EGFR therapy by whole genome sequencing (plasma-Seq) and ultra-sensitive deep sequencing of genes associated with resistance to anti-EGFR treatment such as KRAS, BRAF, PIK3CA, and EGFR. Surprisingly, we observed that the development of resistance to anti-EGFR therapies was associated with acquired gains of KRAS in four patients (40%), which occurred either as novel focal amplifications (n = 3) or as high level polysomy of 12p (n = 1). In addition, we observed focal amplifications of other genes recently shown to be involved in acquired resistance to anti-EGFR therapies, such as MET (n = 2) and ERBB2 (n = 1). Overrepresentation of the EGFR gene was associated with a good initial anti-EGFR efficacy. Overall, we identified predictive biomarkers associated with anti-EGFR efficacy in seven patients (70%), which correlated well with treatment response. In contrast, ultra-sensitive deep sequencing of KRAS, BRAF, PIK3CA, and EGFR did not reveal the occurrence of novel, acquired mutations. Thus, plasma-Seq enables the identification of novel mutant clones and may therefore facilitate early adjustments of therapies that may delay or prevent disease progression.     

Synergetic effects of TDZ with various phytohormones on high-frequency plant regeneration from mature nodal explants of Capparis decidua and their ex vivo implications

Plant Cell, Tissue and Organ Culture (PCTOC) - Capparis decidua (Forssk.) Edgew., is a well-known ornamental shrub of arid and semi-arid horticulture and agroforestry. This paper represents the...